The gut microbiome field is shifting from association to modulation. Microbiota-based treatments come in many shapes and sizes, ranging from dietary intervention to live bacterial products. Recent methodological advances are instrumental to developing innovative new treatment strategies in microbiome-linked pathologies.
Key advances
-
Isotope tracing enabled mapping of nutrient routes in the mouse gut microbiota in vivo3.
-
Engineered Escherichia coli strains enable in vivo recording of transcriptional responses throughout the murine gastrointestinal tract5.
-
CRISPR-edited lactococci encoding β-lactamases control microbiota damage of ampicillin treatment, lowering susceptibility to Clostridioides difficile in mouse models6.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gilbert, J. A. et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature 535, 94–103 (2016).
Tramontano, M. et al. Nutritional preferences of human gut bacteria reveal their metabolic idiosyncrasies. Nat. Microbiol. 3, 514–522 (2018).
Zeng, X. et al. Gut bacterial nutrient preferences quantified in vivo. Cell 185, 3441–3456.e19 (2022).
Vieira-Silva, S. et al. Species–function relationships shape ecological properties of the human gut microbiome. Nat. Microbiol. 1, 16088 (2016).
Schmidt, F. et al. Noninvasive assessment of gut function using transcriptional recording sentinel cells. Science 376, eabm6038 (2022).
Cubillos-Ruiz, A. et al. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis. Nat. Biomed. Eng. 6, 910–921 (2022).
Pan, M. et al. Genomic and epigenetic landscapes drive CRISPR-based genome editing in Bifidobacterium. Proc. Natl Acad. Sci. USA 119, e2205068119 (2022).
He, M. et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109–113 (2013).
Rubin, B. E. et al. Species- and site-specific genome editing in complex bacterial communities. Nat. Microbiol. 7, 34–47 (2022).
Lam, K. N. et al. Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Rep. 37, 109930 (2021).
Acknowledgements
J.R. thanks the Raes lab, and especially N. Prochazkova, for enticing scientific discussions contributing to this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Raes, J. Nifty new tools for microbiome treatment design. Nat Rev Gastroenterol Hepatol 20, 77–78 (2023). https://doi.org/10.1038/s41575-022-00735-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-022-00735-2
